Ozempic as a 'dream': separating GLP-1 hype from clinical fact

What did @skilsiii actually say?

Honestly? Not much, medically speaking. The transcript reads like song lyrics or spoken word: "I'm back in Chicago, I feel it / Another legend I've been, I was in it / I wake up until the end of beginning." There is no medical claim, no dosing advice, no before-and-after narrative. The only health-adjacent signal here is the hashtag #ozempic and the GLP-1 category tag applied to the video.

So we are not fact-checking a claim so much as fact-checking a vibe. The creator seems to be expressing something personal, possibly aspirational, about Ozempic. The caption says "my dream" with a saluting emoji. That's the whole medical content of this video. Which is either refreshingly honest or a missed opportunity to say something useful, depending on your perspective.

Does the science back this up?

There is no specific claim to evaluate against the literature, but the broader cultural moment this video exists in is worth examining. GLP-1 receptor agonists like semaglutide have a genuinely strong evidence base.

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) found that once-weekly semaglutide 2.4 mg produced an average body weight reduction of 14.9% over 68 weeks in adults with obesity, compared to 2.4% in the placebo group. That is a real, replicable finding. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide achieved up to 22.5% weight reduction at the highest dose. These are not trivial numbers.

So if @skilsiii's "dream" is meaningful, sustained weight loss through a GLP-1 medication, the science says that dream is achievable for many people. It is also not a guarantee, and it comes with a side effect profile, a cost burden, and a supply chain that has been notoriously unreliable.

What did they get wrong (or right)?

They got nothing medically wrong, because they said nothing medically specific. That is either a feature or a bug. There is no misinformation to correct here, which puts this video in a category that is genuinely hard to evaluate: content that generates GLP-1 interest without providing any information about GLP-1 medications.

What is worth noting is the pattern this represents. TikTok is saturated with Ozempic content that ranges from rigorous patient experience reporting to dangerous dosing advice shared by people with no clinical background. This video sits in a quieter, less harmful corner. But it also does nothing to help viewers understand what semaglutide actually is, how it works (GLP-1 receptor agonists slow gastric emptying and act on appetite-regulating pathways in the brain), or what the realistic expectations are for treatment outcomes.

Aspiration without information is not dangerous, but it is not particularly useful either.

What should you actually know?

If you found this video and you are curious about GLP-1 medications, here is what the research actually says. Semaglutide and tirzepatide work for a significant portion of people with obesity or type 2 diabetes, but they are not miracle drugs and they are not for everyone.

Common side effects include nausea, vomiting, and gastrointestinal discomfort, particularly in the early weeks of treatment. The STEP trials documented nausea in roughly 44% of semaglutide participants versus 16% in placebo groups. Medications also need to be maintained. A follow-up to STEP 1 (Wilding et al., 2022, Diabetes, Obesity and Metabolism) showed that two-thirds of the weight lost was regained within a year of stopping semaglutide.

Compounded versions of semaglutide circulating online are not equivalent to FDA-approved Ozempic or Wegovy. They are not interchangeable. Anyone considering a GLP-1 medication should have a conversation with a licensed clinician, not base their decision on a TikTok salute and a hashtag.